What the research found

Secukinumab—a monoclonal antibody that blocks IL-17A—met its primary endpoint in relapsed polymyalgia rheumatica, with roughly 41% of treated patients achieving sustained remission at 52 weeks compared to 20% on placebo. Both the 300 mg and 150 mg doses performed similarly. The trial enrolled 381 patients with recurrent PMR (those who flared while tapering prednisone) across 28 countries in a double-blind design. Patients also followed a standardised 24-week prednisone reduction schedule, and about a third were concurrently on stable methotrexate.

Beyond remission rates, secukinumab reduced cumulative prednisone exposure by roughly 20% annually and cut the need for escape medication in half. Patient-reported outcomes—fatigue and functional ability—also improved meaningfully, exceeding thresholds that typically matter clinically. The trial's methodology appears robust: biomarkers were hidden from investigators to prevent unblinding bias, and dropout was higher in the placebo group (as expected when people relapse), with sensitivity analyses suggesting the results held.

Why it matters for you

If you manage relapsing PMR—the pattern where patients flare despite being on a taper—this trial establishes a new mechanism worth considering. Until now, IL-6 inhibitors were the main non-steroid option; now IL-17A blockade is another tool. The practical implications: you might see roughly a 1-in-5 additional patient achieve remission versus placebo alone, and many of the remainder will need less rescue medication.

The steroid-sparing effect (~489 mg less prednisone annually) is real but modest—don't expect dramatic reductions in cumulative glucocorticoid burden the way you might with other inflammatory conditions. More importantly, the fatigue and functional improvements matter for quality of life tracking: if you're monitoring FACIT scores or activity capacity, secukinumab showed consistent gains. The trial design also concealed inflammatory markers from clinicians, which is worth noting if you use CRP/ESR to guide decisions—you won't have that real-time feedback during treatment the way you might with other biologics.

One limitation: we still don't know how secukinumab stacks up directly against sarilumab (an IL-6 inhibitor). The trial was versus placebo, so the choice between mechanisms remains evidence-free. Also, the trial deliberately excluded people with signs of giant-cell arteritis (which co-occurs in ~12% of PMR cases), so these results apply only to "pure" PMR.

Caveats

• No head-to-head comparison: This trial answers whether secukinumab beats placebo, not whether it's better than the existing IL-6 inhibitor option. That comparative evidence doesn't exist yet.
• Relapsed population only: Enrolled patients who flared on the taper, not those starting treatment upfront. Results may not apply to newly diagnosed PMR.
• GCA excluded: Trial deliberately excluded giant-cell arteritis features, so these findings are in uncomplicated PMR only.
• Fungal infection risk: IL-17A plays a role in fungal immunity; this is a known concern class-wide and will require monitoring.
• Industry-sponsored: Novartis designed, funded, and analysed the trial; standard for Phase 3 but worth noting.
• Modest steroid-sparing: The absolute prednisone reduction was smaller than seen in some other IL-6 trials, and confounded by the protocolised taper schedule.